HIV prevention pills offered in the ER: a small step forward

NCT ID NCT04429971

Completed Prevention Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether offering HIV prevention medication (PrEP) in the emergency department is feasible. 26 adults at high risk for HIV were enrolled. The goal was to see if people would start PrEP and follow up with a clinic within 30 days. The study aimed to overcome common barriers like lack of access to regular healthcare.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: emtricitabine/tenofovir (PrEP medication)
What this could lead to: If successful, this approach could make it easier for people at high risk of HIV to start prevention medication without needing a separate doctor's visit.
What could go wrong: This was a very small pilot study with only 26 participants, so results may not apply to everyone. It only tested if the idea was feasible, not if it actually prevents HIV infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS posterior leukoencephalopathy syndrome HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV/AIDS PREP

Contacts and locations

Locations

Mount Sinai Beth Israel Hospital

New York, New York, 10003, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.